Zotinea 100 Capsule contains Itraconazole 100 mg, an antifungal agent belonging to the triazole class, indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Zotinea 100 is effective against a broad spectrum of fungal pathogens, including dermatophytes, yeasts such as Candida species, and molds like Aspergillus. It is commonly prescribed for conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and other invasive fungal infections. The capsule formulation facilitates oral administration with good bioavailability when taken with food. Dosage and duration of therapy depend on the type and severity of infection and should be determined by a healthcare professional. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions must be considered due to itraconazole’s effect on cytochrome P450 enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy. Zotinea 100 Capsule should be used under medical supervision to ensure efficacy and safety.